Treatment of @entity323 after kidney transplantation with intracavernosal self-injection of XXXX .

@entity1 @entity323 @entity251 @entity205 @entity5015 @entity3302 @entity158 @entity1011
PURPOSE: We evaluate the results of treatment of @entity323 in kidney transplant @entity1 with intracavernosal self-injection of vasoactive drugs. MATERIALS AND METHODS: We evaluated and treated 26 male kidney transplant @entity1 for @entity323 . All @entity1 had stable kidney function 6 to 75 months (mean 26.6 +/- 9) after transplantation. Each @entity1 received an intracavernosal injection of 20 microg. @entity5015 ( @entity5015 ), and after 20 to 30 minutes the response was assessed. Nonresponders received 40 microg. @entity5015 at another visit, and those who showed no response were reinjected with 40 microg. @entity5015 plus 30 mg. @entity3302 . A total of 21 @entity1 were enrolled in a self-injection program and have been followed between 3 and 21 months (mean 11.6 +/- 2.7). RESULTS: Hormonal alterations were seen in 7 patients with serum @entity251 as low as 16.6 ng./ml. (normal 33 to 100), and @entity251 injections gave only marginal response in 2. Intracavernosal injection of 20 microg. @entity5015 provided good response in 15 @entity1 (57.7%), while 40 microg. @entity5015 alone or in combination with 30 mg. @entity3302 resulted in good response in another 6 and 2 @entity1 , respectively. Among the 21 @entity1 who were enrolled in the self-injection program 19 (90.5%) reported complete satisfaction with no adverse local or systemic complications except for @entity158 at the injection site in 4. There has been no change in serum @entity1011 , @entity205 level or doses of immunosuppression medications during the observation period. CONCLUSIONS: Intracavernosal self-injection of @entity5015 is well accepted and tolerated by kidney transplant @entity1 . It poses no apparent risks to the transplanted kidney and could be a good modality to treat @entity323 in kidney transplant recipients.
